Rivaroxaban was associated with a higher annual incidence of bleeding events compared to edoxaban (4.88 vs. 3.73 patient-years; P<0.05) in outpatients with non-valvular atrial fibrillation.
Observational (n=724)
No
Does edoxaban compared to rivaroxaban, with dose adjustments based on plasma concentration monitoring, reduce bleeding events in patients with non-valvular atrial fibrillation?
Plasma concentration monitoring of edoxaban and rivaroxaban allows for safe off-label dose reductions that decrease bleeding risk without increasing thromboembolic events in patients with non-valvular atrial fibrillation.
Absolute Event Rate: 4.88% vs 3.73%
p-value: p=<0.05
Monitoring the PCs of rivaroxaban and edoxaban in NVAF patients enables dose adjustments to reduce bleeding risk. The incidence of bleeding under drug PC monitoring was less in the edoxaban than rivaroxaban group.
Suwa et al. (Wed,) conducted a observational in Non-valvular atrial fibrillation (n=724). Rivaroxaban vs. Edoxaban was evaluated on Annual incidence of bleeding events (p=<0.05). Rivaroxaban was associated with a higher annual incidence of bleeding events compared to edoxaban (4.88 vs. 3.73 patient-years; P<0.05) in outpatients with non-valvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: